Gemonic alteration, molecular subtypes and drug sensitivity in breast cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26461949
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: National Hospital Organization, Kyushu Cancer Center (2015-2016); Kyushu University (2014)
• Principal Investigator: Tokunaga Eriko 独立行政法人国立病院機構(九州がんセンター臨床研究センター), その他部局等, 乳腺科部長 (50325453)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 乳癌 / DNA修復

Outline of Final Research Achievements

Extent of the genomic alterations and loss of heterozygosity (LOH) at tumor suppressor gene (TSG) loci was quite different among subtypes in the primary breast cancer. Low-grade hormone receptor (HR)-positive/HER2 negative subtype has significantly less genomic alterations and LOH at TSG loci compared with other subtypes. HER2 type and triple negative (TN) type have extensive genomic and chromosomal alterations and LOH. In these subtypes, cytotoxic chemotherapy is often used. Some tumors with high genomic alterations are sensitive to chemotherapy, thus genomic abnormalities are not always associated with poor prognosis in HER2 and TN subtypes. On the other hand, in HR-positive/HER2 negative subtype, high genomic alterations are significantly associated with poor prognosis. It suggests that tumors with high genomic alterations are probably resistant to endocrine treatment, which may lead to unfavorable outcomes.

Free Research Field

乳癌